IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Simon Lodewijk SCHARPÉ

Ingrid A.J. DE MEESTER

Anne-Marie V.R. LAMBEIR : SERINE PEPTIDASE MODULATORS

Koen J.L. AUGUSTYNS

Achiel J.M. HAEMERS :

Filip J.A. GOOSSENS

Dirk F. HENDRIKS :

Alexandre A. BELIAEV

Serial No. Not Yet Assigned

Filed Concurrently Herewith

Pittsburgh, Pennsylvania

April 18, 2001

PRELIMINARY AMENDMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

Prior to initial examination, please amend the above-identified patent application as follows:

IN THE SPECIFICATION:

Please insert section headings and amend specification paragraphs as follows. (Pursuant to 37 CFR 1.121, marked-up versions of the amended specification paragraphs are attached.)

On page 1, after the title, please insert the following section heading and specification paragraph.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of United States Application Serial No. 09/623,752, received September 8, 2000 which is the national phase of International Patent Application No. PCT/EP99/01617, filed on March 9, 1999, entitled "Serine Peptidase Modulators" and designating, *inter alia*, the United States, which claims priority to European Patent Application Serial No. 98200733.8, filed March 9, 1998.

On page 4, after the second complete paragraph, insert the following section heading:

SUMMARY OF THE INVENTION

On page 5, please delete the second complete paragraph and insert the following replacement paragraph:

It was then found that compounds of the present invention are very potent modulators, in particular inhibitors, of serine peptidases/proteases in general and DPP IV, DPP II, PO, FAPα, lysosomal Pro-X carboxypeptidase and elastase in particular.

On page 5, after the third complete paragraph, insert the following section heading:

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

After the paragraph bridging pages 23 and 24, insert the following section heading:

BRIEF DESCRIPTION OF THE DRAWINGS

REMARKS

The specification has been amended to place the application in conformance with standard United States patent practice.

Examination and allowance of pending claims 1-26 are respectfully requested.

Respectfully submitted,

WEBB ZIESENHEIM LOGSDON ORKIN & HANSON, P.C.

Barbara E Johnson

Registration No. 31,198

Attorney for Applicants 700 Koppers Building

436 Seventh Avenue

Pittsburgh, PA 15219-1818

Telephone: 412-471-8815 Facsimile: 412-471-4094

MARKED-UP AMENDED SPECIFICATION PARAGRAPH

Page 5, second complete paragraph

It was then found that compounds [as claimed in claim 1] of the present invention are very potent modulators, in particular inhibitors, of serine peptidases/proteases in general and DPP IV, DPP II, PO, FAP α , lysosomal Pro-X carboxypeptidase and elastase in particular. [The compounds as listed in claim 12 were found to be potent inhibitors of DPP IV and PO.]